Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide.
Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of metastatic ovarian cancer, results in a devastating 15%-20% survival rate. Therapeutics that restore genes inactivated during oncogenesis are predicted to be more potent and specific than curr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2004-02-01
|
| Series: | PLoS Biology |
| Online Access: | http://europepmc.org/articles/PMC340944?pdf=render |